MAGI2 and myeloid sarcoma: Specifically, polymorphisms in CD86 (rs1129055), CLEC16A (rs6498169), CTSS (rs2275235 and rs1415148), EOMES (rs2371108), MBP (rs470929 and rs1789084), FAS (rs982764), TRBC1 (rs71878), IL1R1 (rs956730), IL12RB2 (rs946685), IL22RA2 (rs202573), PTPRT (rs1117602254), PVT1 (rs2114358), ALOX5AP (rs10162089), MAGI2 (rs16886004), ZAK (rs139890339), RFPL3 (rs73166319), UVRAG (rs80191572), SLC1A4 (rs759458), and HLA-DRB1*1501 (rs3135391 and rs3135388) showed a statistically significant association with a response to GA treatment in patients with MS.